[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-surgery":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,48,80,107,135,157,182,206,234,258,282],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100054134","appropriateness-of-hemostatic-agent-use-in-cardiovascular-surgery-haemovax-100054134",false,"NCT07699016","Appropriateness of Hemostatic Agent Use in Cardiovascular Surgery (HAEMOVAX)","Evaluation of Appropriateness in the Use of Hemostatic Agents in Cardiovascular Surgery: A Mixed-Methods Single-Center Observational Study","HAEMOVAX","Inclusion Criteria:\n\n* Physicians with a surgical role in the Departments of Cardiac Surgery or Vascular Surgery at IRCCS Galeazzi-Sant'Ambrogio, Milan Including attending surgeons, consultant surgeons, and surgical residents\n* Active participation in cardiovascular operative procedures during the study period (or within the preceding 12 months)\n* Employment at the study institution at the time of survey administration Willingness to participate and complete the anonymous structured questionnaire\n\nExclusion Criteria:\n\n* Non-surgical healthcare personnel (e.g., nurses, anesthesiologists, administrative staff, or allied health professionals)\n* Surgeons not involved in operative cardiovascular practice during the study period\n* External collaborators or visiting surgeons without regular clinical activity at the institution\n* Individuals who do not provide informed consent for participation in the anonymous survey\n* Questionnaires with missing or incomplete vignette responses preventing calculation of the KPA-Score",true,"ALL","18 Years",{"count":21,"type":22},15,"ESTIMATED","OBSERVATIONAL","Hemostatic agents are widely used in cardiac and vascular surgery to support intraoperative bleeding control. Despite their clinical relevance and substantial economic impact, little is known about real-world patterns of use, adherence to evidence-based recommendations, and the alignment between clinicians' perceived knowledge and actual decision-making.\n\nHAEMOVAX is a single-center mixed-methods observational study conducted at IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. The study combines an anonymous survey of cardiovascular surgeons with a retrospective audit of institutional hemostatic agent consumption. The primary objective is to evaluate the appropriateness of hemostatic agent selection using a Knowledge-Practice Alignment Score (KPA-Score) derived from standardized clinical vignettes based on current EACTS and ESA recommendations. Secondary objectives include assessment of usage patterns, barriers to appropriate use, concordance between declared practice and real-world consumption, and opportunities for evidence-based standardization.",[26,27,28,29,30],"Hemostasis","Perioperative Bleeding","Cardiovascular Surgery","Cardiac Surgery","Vascular Surgery",[32,33,34,27],"Hemostatic Agents","Surgical Hemostasis","Topical Hemostatic Agents","RECRUITING","2026-07-07",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":22},"2026-07-01",{"date":43,"type":22},"2026-08-15",{"name":45,"class":46},"University of Milan","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100630117","the-effects-of-a-6-week-pre-operative-administration-of-a-microbiome-modulator-wellbiome-versus-placebo-on-cardiac-surgical-outcomes-and-nhs-cost-savings-100630117","NCT07483502","The Effects of a 6-week Pre-operative Administration of a Microbiome Modulator \"WellBiome\" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings.","A Double Blind, Placebo Controlled 6- Week Pre-operative Randomised Clinical Trial of a Microbiome Modulator \"WellBiome\" Versus Placebo on Cardiac Surgical Outcomes and NHS Cost Savings.","INCLUSION CRITERIA:\n\n* Aged 50-80\n* BMI ≥ 25-40kg\u002Fm²\n* Waist circumference \\>94cm (men) and 88cm (women)\n* HbA1c 42-58 mmol\u002Fmol (6.0-7.5 old HbA1c units)\n* No known intolerances to oligosaccharides and xylooligosaccharides\n* Be stable dose of cholesterol and blood pressure medication for 3 months\n* Be willing to participate and sign to that effect.\n\nEXCLUSION CRITERIA\n\n* Active cancer\n* Any gastro-intestinal surgery or currently under the care of the GI clinical team for any clinically significant digestive issue (Crohn's, IBS, ulcerative colitis).\n* On or had antibiotic treatment in the last 3 months.\n* Patients who have taken ibuprofen in the last week or any condition that increases the likelihood of regular or sustained use during the intervention.\n* On proton pump inhibitors (Omeprazole, Esomeprazole, Lansoprazole, Rabeprazole, Pantoprazole) within the last one month on long acting non-steroidal anti-inflammatory drugs in the last month or any condition that increases the likelihood of regular use during the intervention.\n* Taking any prebiotic or probiotic supplementation within the last three months\n* Patients who are vegetarians or vegans","50 Years","80 Years",{"count":58,"type":22},80,"INTERVENTIONAL",[61],"NA","More than 7.4 million people in the UK are currently waiting for surgery. Behind that number are real people-patients preparing mentally and physically for procedures ranging from joint replacements to major heart and abdominal operations.\n\nThis research forms part of a broader strategy known as prehabilitation - preparing the body before surgery to improve outcomes afterward. For patients waiting for surgery, it represents a shift from passive waiting to active preparation.\n\nHeart surgery for bypass or valve replacements results in inevitable yet controlled trauma. It increases inflammation, stress hormones and immune system demand. The body then has to repair itself - quickly and efficiently. And here's the surprising part. Inside your gut live trillions of bacteria - called your gut microbiome. These bacteria help regulate inflammation, strengthen your immune system and protect against infection.\n\nThis randomised clinical trial is investigating a fascinating question:\n\nCan improving your gut microbiome through consumption of fibre before surgery help you recover faster, reduce time in ICU, shorten hospital stays, and lower complication rates? The placebo controlled trial will randomise 80 patients following eligibiilty checks to either 5g of prebiotic fibre\u002F300mg of magnesium (WellBiome) OR 5g of maltodextrin for a period of 6-8 weeks prior to surgery. Patient will provide blood, urine and faecal samples at baseline and upon admission for surgery, and two further blood samples at day 3 and 6 post operatively.\n\nFollowing surgery, patient outcomes will be assessed and compared between the experimental group (prebiotic fibre\u002Fmagnesium) and placebo group (maltodextrin). The investigators are focussing on the time spent in the intensive care unit, complications and overall hospital stay. By documenting and quantifying these the investigators can calculate the costs and any savings between the groups.",[64,28],"Cardiovascular Diseases (CVD)",[66,67,68,69],"Cardiac surgery","Surgical outcomes","Nutritional prehabilitation","Microbiome","2026-06-22",{"date":72,"type":39},"2026-06-23",{"date":74,"type":39},"2026-04-09",{"date":76,"type":22},"2026-12-18",{"name":78,"class":79},"Hull University Teaching Hospitals NHS Trust","OTHER_GOV",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":47},"100638019","fascial-plane-blocks-in-cardiac-surgery-100638019","NCT07622823","Fascial Plane Blocks In Cardiac Surgery","The Effect Of Combined Rectus-Intercostal Fascial Plane Block Or Rectus Sheatf Block With A Pectoral-Intercostal Fascial Plane Block In Cardiac Surgery On Postoperative Opioid Consumption, Quality Of Recovery, And Chronic Pain: A Prospective, Observational Study","Inclusion Criteria:\n\n* elective cardiac surgery planned\n* over 18 years, adult\n* American Society of Anaesthesiology (ASA) score I-III\n\nExclusion Criteria:\n\n* under 18 years of age,\n* ASA IV and above,\n* contraindications for the block application\n* history of cardiac surgery,\n* reoperated due to surgery-related complications after emergency surgery or postoperative elective surgery,\n* off-pump cardiac surgery or minimally invasive cardiac surgery\n* unable to be extubated in the intensive care unit at 24 hours postoperatively\n* history of chronic pain treatment\n* chronic alcoholism and substance abuse\n* declining to give written informed consent",{"count":88,"type":22},90,"The aim of the present study is to evaluate the effects of the recto-intercostal fascial plane block (RIFPB) or the rectus sheath block (RSB) combined with the pectoral-intercostal fascial plane block (PIFPB) on postoperative analgesia in patients undergoing cardiac surgery.",[28,91,92],"Regional Anaesthesia","Postoperative Analgesia",[94,95,96,97,98],"cardiovascular surgery","pectoral-intercostal fascial plane block","recto-intercostal fascial plane block","rectus sheath block","postoperative analgesia","2026-06-01",{"date":101,"type":39},"2026-06-03",{"date":99,"type":39},{"date":104,"type":22},"2026-12-01",{"name":106,"class":46},"Antalya Health Sciences University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":18,"minAge":55,"maxAge":56,"enrollmentInfo":114,"targetDuration":4,"studyType":59,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":47},"100631227","nutritional-effects-in-cardiovascular-surgery-100631227","NCT07497932","Nutritional Effects in Cardiovascular Surgery","Nutritional Intervention in the Modulation of Postoperative Metabolism in Cardiovascular Surgery","Inclusion Criteria:\n\n* Scheduled to undergo cardiovascular surgery\n* Completed preoperative clinical and imaging evaluations\n* Willing to provide informed consent\n* Willing to receive potential probiotic supplementation\n\nExclusion Criteria:\n\n* Use of antibiotics, probiotics, or other treatments affecting gut microbiota within 4 weeks\n* History of major gastrointestinal disease",{"count":115,"type":22},30,[61],"This study aims to investigate the distribution of gut microbiota-derived metabolites, and to evaluate whether postoperative nutritional intervention can modulate the gut-heart metabolic axis, thereby improving metabolic profiles and clinical outcomes.",[28,119],"Cardiovascular Disease",[121,122,123,124,125],"Gut microbiota-derived metabolites","Metabolomics","Cardiovascular disease","Nutritional intervention","Mass spectrometry","2026-03-23",{"date":128,"type":39},"2026-03-27",{"date":130,"type":39},"2026-03-19",{"date":132,"type":22},"2026-12-31",{"name":134,"class":46},"Fu Jen Catholic University",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":142,"targetDuration":144,"studyType":23,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":47},"100618348","cardiovascular-surgery-early-prediction-system-for-aki-cards-aki-registry-100618348","NCT07330453","Cardiovascular Surgery Early Prediction System for AKI :CARDS-AKI Registry","Early Prediction and Clinical Outcomes of Cardiovascular Surgery-Associated Acute Kidney Injury: A Prospective Multicenter Cohort Study","Inclusion Criteria:\n\n* Age ≥ 18 years；\n* Scheduled to undergo elective cardiac surgery；\n* Able to complete baseline data collection and provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative serum creatinine \\> 353 μmol\u002FL, history of or currently receiving dialysis therapy.\n* History of kidney transplantation.\n* Presence of malignant tumors.",{"count":143,"type":22},5000,"2 Years","This multicenter, prospective study prospectively enrolled patients undergoing cardiovascular surgery. Detailed perioperative clinical data and biospecimens were collected at multiple time points. The primary aim is to develop an early warning model for postoperative acute kidney injury (AKI) by integrating clinical data and biomarkers. Additionally, through long-term follow-up, the study seeks to characterize outcome trajectories and establish a prognostic model for AKI patients.\n\nThis study addresses four key questions: 1) Integration of clinical information and biomarkers to develop an early predictive model for cardiac surgery-associated acute kidney injury (CSA-AKI); 2) Identification of risk factors for CSA-AKI occurrence; 3) Determinants of prognosis in patients with CSA-AKI; and 4) Enhanced prediction of near- and long-term clinical event risks in this patient population.\n\nParticipants will receive standard perioperative management. The study protocol includes the following procedures:(1) Clinical Data Collection: Comprehensive perioperative clinical data will be systematically recorded. (2) Biospecimen Sampling: Serial blood and urine samples will be obtained at predefined time points throughout the perioperative period. (3) In-Hospital Monitoring: Clinical outcomes will be continuously monitored during the hospital stay. (3) Post-discharge Follow-up: Participants will be assessed at regular intervals after discharge to track the occurrence of major adverse events.\n\nThese findings provide a foundational basis for the development of a data-driven early-warning system. Such a system is designed to facilitate the prompt identification of high-risk patients and enable the initiation of personalized treatment strategies, thereby potentially improving clinical outcomes and optimizing resource allocation",[28],"NOT_YET_RECRUITING","2026-01-04",{"date":150,"type":39},"2026-01-09",{"date":152,"type":22},"2025-12-25",{"date":154,"type":22},"2029-07-31",{"name":156,"class":46},"Chinese Academy of Medical Sciences, Fuwai Hospital",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":47},"100572879","ai-model-for-assessing-cardiac-surgeons-techniques-100572879","NCT06739005","AI Model for Assessing Cardiac Surgeons' Techniques","artifiCiAl Intelligence Model for Evaluating the Surgical Techniques of caRdiAc Surgeons (CAMERA)","CAMERA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing internal mammary artery-to-left anterior descending artery bypass grafting\n* First-time recipient of isolated CABG surgery\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Patients with acute coronary syndrome\n* Patients with contraindications to coronary CT angiography or coronary angiography\n* Patients with renal insufficiency or active liver disease, including those with persistently elevated serum transaminases of unknown cause or any serum transaminase levels exceeding three times the upper limit of normal.",{"count":166,"type":22},284,"The goal of this study aims to investigate the use of artificial intelligence to analyze and evaluate the characteristics and proficiency of surgeons during vascular anastomosis in coronary artery bypass grafting (CABG) procedures. The main question it aims to answer is:\n\nConsistency assessment between AI evaluation scores and human expert evaluation scores for surgeons during left anterior descending (LAD) artery anastomosis.",[169,170,28,171,172],"CABG-patients","CABG","Surgeons","Artificial Intelligence (AI)","2025-09-19",{"date":175,"type":39},"2025-09-23",{"date":177,"type":39},"2025-01-09",{"date":179,"type":22},"2027-07",{"name":181,"class":79},"China National Center for Cardiovascular Diseases",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":17,"sex":18,"minAge":189,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":47},"100569289","exploring-the-predictive-value-of-electroencephalography-features-in-perioperative-neurocognitive-disorders-following-cardiovascular-surgery-100569289","NCT06692309","Exploring the Predictive Value of Electroencephalography Features in Perioperative Neurocognitive Disorders Following Cardiovascular Surgery","To Explore the Predictive Value of Electroencephalography Features in Perioperative Neurocognitive Disorders in Patients Undergoing Cardiovascular Surgery Under General Anaesthesia: a Single-centre Prospective Observational Study","Inclusion Criteria:\n\n1. Written informed consent\n2. undergoing coronary artery bypass surgery or valve replacement surgery under general anaesthesia\n3. ASA grade: II-IV\n4. older than 60 years\n5. Able to complete cognitive function tests\n\nExclusion criteria:\n\n1. history of severe neurological diseases and psychiatric diseases\n2. history of drug abuse\n3. severe hearing or vision impairment\n4. preoperative delirium\n5. serious adverse reactions such as cardiac arrest and cardiopulmonary resuscitation during surgery\n6. patients undergoing secondary surgery in a short period\n7. participation in concurrent clinical trials","60 Years",{"count":191,"type":22},100,"To explore the predictive value of Electroencephalography features in Perioperative Neurocognitive Disorders in patients undergoing cardiovascular surgery under general anesthesia",[28,194],"Perioperative Neurocognitive Disorders",[196],"Perioperative Neurocognitive Disorders;Electroencephalography","2025-05-25",{"date":199,"type":39},"2025-05-30",{"date":201,"type":39},"2023-03-01",{"date":203,"type":22},"2026-02-28",{"name":205,"class":46},"Beijing Chao Yang Hospital",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":59,"phases":215,"briefSummary":216,"conditions":217,"keywords":221,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":233},"100571677","protective-effect-of-angong-niuhuang-against-negative-inflammatory-response-and-neurologic-dysfunction-after-cardiovascular-surgery-100571677","NCT06723366","Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery","Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery (PANDA X)","Inclusion Criteria:\n\n* (1) an age \\> 18 years,\n* (2) underwent cardiovascular surgery,\n* (3) diagnosis of acute neurologic dysfunction, including but not limited acute cerebral infarction of the internal carotid artery system,\n* (4) a National Institutes of Health Stroke Scale (NIHSS) score ranging from 10 to 20,\n* (5) a time from symptom onset to randomization within 36 h,\n* (6) provision of informed consent.\n\nExclusion Criteria:\n\n* (1) not suitable for taking ANP after the dialectical process by a traditional Chinese medical doctor,\n* (2) received ANP within 1 month before stroke onset,\n* (3) liver failure,\n* (4) declined to participate in this study.",{"count":214,"type":22},120,[61],"Neurologic Dysfunction is one of the main factors contributing to poor outcomes in cardiac surgery patients, except for heart failure. Atherosclerosis of the aorta, a history of cerebral infarction, and cervical artery disease are common clinical risk factors for cerebral neurological dysfunction after cardiac surgery. Results of preclinical studies suggested that Angong Niuhuang Pills (ANPs), a traditional Chinese patent medicine, including realgar, cinnabaris, Bovis Calculus, artificial Moschus, and powdered buffalo horn extract, decreased infarct volume and cerebral edema, and presented anti- atherosclerosis and cardio-protective effects in clinical and preclinical studies. The PANDA X trial is designed as a pilot study to explore the safety and efficacy of ANP in patients with moderate-to-severe neurologic dysfunction after cardiovascular surgery.",[218,28,219,220],"Cardio-pulmonary Bypass","Cerebral Protection","Brain Injury",[222,223],"Inflammatory Response","cardiopulmonary bypass","2024-12-09",{"date":226,"type":39},"2024-12-12",{"date":228,"type":22},"2025-01-01",{"date":230,"type":22},"2025-12-31",{"name":232,"class":46},"Nanjing Medical University",2,{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":241,"targetDuration":243,"studyType":23,"phases":4,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":4},"100568748","development-of-perioperative-delirium-prediction-model-100568748","NCT06685263","Development of Perioperative Delirium Prediction Model","Development of a Perioperative Delirium Prediction Model in Patients Undergoing Cardiovascular Surgery","Inclusion Criteria:\n\n* Over 18 years old\n* Previous cardiovascular surgery\n* No mental deficiency and visual and hearing impairment\n* Participants' acceptance to participate in the research\n* The patient is not in coma (RASS score between -3 and +4, GCS score of 10 and above)\n\nExclusion Criteria:\n\n* Cardiovascular surgery under emergency conditions\n* Being diagnosed with delirium, dementia, psychiatric illness and taking medication for this reason before the surgery\n* Serious conditions such as cardiopulmonary resuscitation during surgery\n* Alcohol and drug addiction\n* Duration of mechanical ventilation exceeding 36 hours\n* Dying in the intensive care unit within 24 hours",{"count":242,"type":22},770,"3 Days","Postoperative delirium is an acute organic brain dysfunction that is commonly observed following cardiovascular surgery. It presents with acute and fluctuating changes in the level of consciousness, resulting in impaired cognitive function and perception. The incidence of delirium following cardiac surgery has been reported to range from 11.4% to 55%. In light of the challenges associated with treating delirium once it has manifested, it is imperative to prioritise the early recognition and prevention of this condition. The objective of this study was to develop a perioperative delirium risk prediction model for patients undergoing cardiovascular surgery.",[28],[94,247,248],"delirium","prediction model","2024-11-09",{"date":251,"type":39},"2024-11-12",{"date":253,"type":22},"2024-12-15",{"date":255,"type":22},"2026-05-30",{"name":257,"class":46},"Kubra Gunes",{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":59,"phases":267,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":47},"100562316","effectiveness-of-a-intraoperative-blood-recovery-system-in-cardiovascular-surgery-in-brazil-100562316","NCT06601582","Effectiveness of a Intraoperative Blood Recovery System in Cardiovascular Surgery in Brazil","Effectiveness of a Intraoperative Blood Recovery System in Cardiovascular Surgery Using Cardiopulmonary Bypass in Brazil. Randomized Crontrolled Trial","Inclusion Criteria:\n\n* all patients undergoing CABG or Valve surgery singly.\n\nExclusion Criteria:\n\n* Emergency cardiac surgery;\n* Previous heart surgery;\n* End-stage chronic kidney disease;\n* Inability to receive a blood transfusion (refusal);\n* Anemia (hemoglobin less than 10g\u002Fdl);\n* Thrombocytopenia (platelet count less than 100,000\u002Fmm3);\n* Coagulopathy (RNI \\> 1.5);",{"count":266,"type":22},60,[61],"Randomized trial to evaluate the effectiveness of a intra operative blood recovery system in reducing the need for allogeneic transfusion in cardiovascular surgeries using cardiopulmonary bypass",[28,270],"Blood Loss, Surgical",[28,272],"Operative Blood Salvage","2024-09-15",{"date":275,"type":39},"2024-09-19",{"date":277,"type":39},"2022-04-01",{"date":279,"type":22},"2024-12-31",{"name":281,"class":46},"Instituto Materno Infantil Prof. Fernando Figueira",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":291,"conditions":292,"keywords":296,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":307,"locationsCount":310},"100413896","physiologic-signals-and-signatures-with-the-accuryn-monitoring-system---the-accuryn-registry-100413896","NCT04669548","Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry","Physiologic Signals and Signatures With the Accuryn Monitoring System - A Retrospective and Prospective Analysis (The Accuryn Registry)","Inclusion Criteria:\n\n1. Signed or Verbal Informed Consent as required by IRB (if applicable).\n2. Adult (age ≥ 18).\n3. Monitored on the Accuryn® Monitoring System during their procedure and ICU stay (for retrospective enrollment).\n4. Patient is undergoing cardiac surgical intervention(s).\n\nExclusion Criteria:\n\n1. Known history of advanced chronic kidney disease defined by an estimated glomerular filtration rate (eGFR) \\\u003C20 mL\u002Fmin\u002F1.73m2 within 30 days prior to procedure.\n2. The patient is unsuitable for the study, in the opinion of the investigator. This may include vulnerable patient populations such as pregnant women, prisoners ,or those detained in a penal institution.",{"count":290,"type":22},2500,"The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.",[293,294,295,28],"Intraabdominal Hypertension","Abdominal Compartment Syndrome","Acute Kidney Injury",[297,170,28,298,299,300],"Acute Kidney Injury (AKI)","Intraabdominal Pressure (IAP)","Urine Output (UO)","Accuryn","2022-09-26",{"date":303,"type":39},"2022-09-28",{"date":305,"type":39},"2020-12-21",{"date":132,"type":22},{"name":308,"class":309},"Potrero Medical","INDUSTRY",9]